Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524224 | 1.00 | ACE (0.44) | ACECA12CA1CA2CA9 | |
| SCHEMBL3739768 | 1.00 | ACE (0.44) | ACECA12CA1CA2CA9 | |
| SCHEMBL20400973 | 0.94 | CA12 (0.41) | ACECA12CA1CA2CA9 | |
| SCHEMBL28429784 | 0.94 | CA12 (0.41) | ACECA12CA1CA2CA9 | |
| SCHEMBL20401099 | 0.86 | ATM (0.32) | ACE | |
| SCHEMBL28432499 | 0.86 | ATM (0.32) | ACE | |
| SCHEMBL28211348 | 0.86 | ACE (0.43) | ACECA12CA1CA2CA9 | |
| SCHEMBL1543546 | 0.82 | ACE (0.56) | ACEREN | |
| SCHEMBL187408 | 0.82 | ACE (0.56) | ACEREN | |
| SCHEMBL750903 | 0.82 | ACE (0.56) | ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111356456-A | 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor | 夏威夷大学 | 2020-06-30 | — | — | CN | disclosed |
| WO-2018136935-A1 | 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9732066-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINY AKU CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| WO-2017046606-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9216968-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINYAKU CO., LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-2746265-B1 | HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR | NIPPON SHINYAKU CO LTD (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20140221339-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2746265-A1 | HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL DRUG | Nippon Shinyaku Co., Ltd. (JP) | 2014-06-25 | — | — | EP | disclosed |
| EP-2421853-B1 | SYNTHESIS OF 3-{[(2R)-1-METHYLPYRROLIDIN-2-YL]METHYL}-5-[2-(PHENYLSULFONYL)ETHYL]-1H-INDOLE | ITALIANA SINT SPA (IT) | 2013-07-24 | — | — | EP | disclosed |
| US-8426612-B2 | Synthesis of 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5[2-(phenylsulfonyl)ethyl]-1H-indole | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2013-04-23 | — | — | US | disclosed |
| WO-2010121673-A1 | SYNTHESIS OF 3-{[(2R)-1-METHYLPYRROLIDIN-2-YL]METHYL}-5-[2-(PHENYLSULFONYL)ETHYL]-1H-INDOLE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221339-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | ACE 934/4885CA12 2512/4885CA1 1088/4885 |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | ACE 934/4885CA12 2512/4885CA1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.